Top Biotech Companies in Singapore (91)
ProfilePrint is an A.I.-driven predictive and prescriptive profiler, providing users with accessible, affordable, and portable solutions to ascertain and predict quality and profile of a food ingredient at the point of use, within seconds. Today, an enormous amount of resources are required to physically grade food samples across multiple stages of the global supply chain. ProfilePrint’s solution redefines transaction standards,...
4baseCare, an Illumina-backed Company* headquartered in Singapore, is engaged in developing cutting-edge Precision Oncology Solutions using Advanced Genomics and Next-Gen digital health technology. Taking into consideration that the clinical outcome could significantly vary across different populations, we have developed a unique set of indigenous comprehensive cancer gene panels that enables oncologists to choose the optimal precision therapies for their patients. Our...
Kemin Industries is a global ingredient manufacturer that strives to sustainably transform the quality of life every day for 80 percent of the world with its products and services. The company supplies over 500 specialty ingredients for human health, food safety and protection of the global food supply chain. Kemin ingredients offer solutions across various industries including animal health, nutraceuticals,...
Umami Bioworks is a marine biotechnology company developing cultivated seafood and other marine-derived biosolutions. Its AI-driven ALKEMYST platform combines genomics, stem cell biology, machine learning, and automation to enable scalable, traceable, cruelty-free production. The company licenses modular systems to manufacturing partners and supports applications in seafood, cosmetics, and nutrition, aiming to reduce overfishing and ecosystem strain while improving sustainable food...
Mobcoder is a global technology company specializing in AI development and innovative solutions. Since 2014, we've launched over 300 apps, empowering businesses across various industries and locations.
A science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. We have three global businesses that research, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products. We aim to bring differentiated, high-quality and needed healthcare products to as many people as possible, with our three global businesses, scientific and technical know-how...
GSK's Top Stability & Growth Strengths
Strong Market Position & Advantage: GSK is positioned as a top-tier global biopharmaceutical company by revenue while showing category leadership in vaccines and HIV, anchored by franchises such as Shingrix and ViiV’s portfolio. Its consistent top-10/12 standing and segment leadership in vaccines, respiratory, and HIV support a stable competitive footing.
Resilient & Sustainable Growth: Revenue and earnings momentum are supported by broad-based growth across Specialty Medicines and continued contributions from Vaccines, alongside reaffirmed multi-year sales ambitions. Guidance for continued turnover and profit expansion indicates an expectation of ongoing, steadier growth rather than a one-off spike.
Healthy Cash Flow: Operating cash generation is described as strong and is being used to fund R&D investment and shareholder returns such as dividends and buybacks. This cash profile supports resilience through investment cycles and potential volatility in specific product areas.
Nuevocor is a new biotech start-up in Singapore striving to develop gene therapies for genetic cardiomyopathies. It will leverage a deep understanding of cardiac cell biology, as well as a technology platform encompassing novel gene therapy vectors and proteomics-based target discovery
Biomed Global is a leading total solution provider in the biomedical and life sciences industry, operating across Southeast Asia. The company provides a holistic range of innovative medical solutions and cutting-edge biomedical technologies spanning research, development, and clinical applications. Its mission is to advance healthcare standards and facilitate medical breakthroughs by bringing together leading-edge medical solutions and expert support to...
Catalent Inc. (NYSE: CTLT), an S&P 500® company, is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health...
Accelerating biological understanding and discovery is more than a mission for 10x Genomics. It’s a commitment. Fueled by equal parts scientific vision and determined passion, we are enabling fundamental research across the life sciences by delivering rapid innovation that allows our customers to resolve complex biology—across the fields of oncology, immunology, neuroscience, and more. As we deliver powerful new methods for...
10x Genomics's Top Stability & Growth Strengths
Strong Market Position & Advantage: 10x is widely regarded as the leader in single‑cell and a co‑leader in spatial biology, with Chromium, Visium and Xenium as reference platforms in many labs. Legal wins and injunctions in spatial further reinforce competitive positioning.
Product Line Growth: Ongoing chemistry and platform updates (GEM‑X, Visium HD, Xenium Protein/RNA multiomics) and launches like next‑gen Chromium Flex indicate continued expansion of content and capabilities. The planned acquisition of Scale Biosciences aims to broaden single‑cell workflows and support medium‑term growth.
Investor Backing & Capital Strength: The company maintains a sizable cash and securities balance alongside a large recurring consumables base. Management is prioritizing cash and costs while guiding quarter‑to‑quarter to navigate a softer funding environment.
ReSync coordinates labs, data, and AI models on one platform. Stop wrangling with emails and spreadsheets – find data and make decisions twice as fast.
Analytical scientists and clinical researchers worldwide rely on Agilent to help fulfill their most complex laboratory demands. Our instruments, software, services and consumables address the full range of scientific and laboratory management needs—so our customers can do what they do best: improve the world around us. Whether a laboratory is engaged in environmental testing, academic research, medical diagnostics, pharmaceuticals, petrochemicals or...
Agilent Technologies's Top Stability & Growth Strengths
Strong Market Position & Advantage: Industry and company materials consistently place Agilent among the top global players in analytical instrumentation—especially in chromatography and mass spectrometry—and as a frequent short‑list vendor for regulated and R&D labs. Recognition such as Instrument Business Outlook’s “Company of the Year” supports this standing.
Diversified Revenue Streams: The portfolio spans instruments, software/informatics, consumables, and services (Agilent CrossLab), with end‑to‑end workflows and specialty CDMO contributions providing multiple revenue levers. This breadth increases switching costs and drives recurring revenue that helps balance capital‑equipment cycles.
Resilient & Sustainable Growth: After a FY2024 decline, revenue returned to growth in FY2025 and continued in Q1 FY2026, with guidance pointing to mid‑single‑digit core growth and margin expansion. CrossLab’s steady growth and an instrument replacement cycle are cited as continuing supports.
Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning more than seven decades, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts,...
Alcon's Top Stability & Growth Strengths
Strong Market Position & Advantage: The business is positioned as a global leader in eye care with meaningful share in contact lenses and one of the largest installed bases in ophthalmic surgical equipment, supporting durable demand across geographies. Scale across Vision Care and Surgical also supports recurring revenue via consumables tied to the installed base.
Resilient & Sustainable Growth: Revenue is described as growing year over year with guidance calling for continued mid-single-digit constant-currency sales growth into 2026, supported by steady demand for essential procedures like cataract surgery. The company is also positioned to outpace broader eye-care market growth expectations per the provided outlook.
Healthy Cash Flow: Cash generation is described as strong, with operating cash flow and free cash flow at sizable levels that support ongoing investment and shareholder returns. This cash profile provides resilience against near-term cost headwinds and funding for launches and efficiency programs.
ChemLex is a Singapore-based company delivering autonomous chemical synthesis services for the pharmaceutical and biotech industry. Our AI-integrated autonomous synthesis platform improves quality, consistency, and productivity while reducing costs and supporting ESG goals.
We are a digital-first, life sciences commercialization company. We help biopharmaceutical, emerging biotech and medical device companies develop products, get them to the market, and grow their impact through the life cycle in a more effective, efficient, and modern way. We bring together healthcare domain expertise, fit-for-purpose technology, and an agile operating model to provide a diverse range of solutions....
Indegene's Top Stability & Growth Strengths
Strong Market Position & Advantage: Independent analyst assessments place the company in leadership cohorts for life sciences commercial AI/analytics and digital services for commercial operations, indicating defensible positioning in its specialization. The company is also described as a best-fit provider for digital commercialization, omnichannel activation, content operations at scale, and AI-driven commercial analytics, reinforcing category leadership within that lane.
Strong Revenue Growth: Revenue shows clear acceleration into FY26, including a strong year-over-year increase in the latest reported quarter and a positive exit rate from prior quarters as deal wins converted. Full-year FY25 results also show year-over-year growth alongside continued profitability, supporting an upward growth trajectory.
Product Line Growth: Capability expansion is evidenced by recent acquisitions intended to deepen data-driven omnichannel, media offerings, and consulting/transformation coverage, broadening the commercialization toolkit. Ongoing scaling post-IPO is also framed as broadening capabilities beyond prior scope within its core focus areas.
Hoosier Cancer Research Network (HCRN) is an independent nonprofit contract research organization specializing in early-phase, multi-center, investigator-initiated oncology clinical trials, with a mission to advance cancer research, education, and patient advocacy.
For over 35 years, IDT has been enabling genomics laboratories with an oligonucleotide manufacturing process unlike anyone else in the industry, with the most advanced synthesis, modification, purification, and quality control capabilities available. Through our founder's dedication to innovation, the highest standards of quality, and deep genomics expertise, IDT has evolved from a leading oligo manufacturer to a genomics solutions provider supporting areas such...
Vulcan Augmetics is building a distribution and data ecosystem for the $156BN biosignal sensor market. Using ML powered wireless EMG sensors with deep learning networks, our goal is to become the gateway between hardware and humanity, providing high fidelity biodata and feedback so that healthcare professionals can make better decisions for their patients, and everyday users can control their devices...
In a rapidly changing industry, caregivers remain the constant. Every day they demonstrate their passion for helping people despite unprecedented pressure to increase access and quality of care with the same or fewer resources. Hillrom is driven by patient-centered care. Everything we do, and all our products and technologies, are designed to enhance outcomes for patients and caregivers. It starts...
Kyberlife's technology arm holds the first open marketplace in Asia with an easy-to-use platform that hosts healthcare vendors, life-science companies & manufacturers globally. Kyberlife also has a distribution arm that facilitates licensed distribution of life-science/pharmaceutical/medical products, Instruments, equipment to the SEA region. Our vision is to provide for the millions of researchers in Asia, SEA & Australasia to shop for...
